Neumedicines

Executive Summary

Neumedicines is a clinical-stage biopharmaceutical company pioneering novel oncology immunotherapeutics that link hematopoiesis with immunity to induce durable anti-cancer responses. Based in Pasadena, California, the company's lead candidate, HemaMax, is a combination immunotherapy designed to leverage the innate immune system for complete tumor clearance. Founded in 2004, Neumedicines has advanced HemaMax through preclinical and early clinical development, positioning it as a potential first-in-class treatment for multiple cancer types. The company's platform approach differentiates it from conventional checkpoint inhibitors and CAR-T therapies by targeting hematopoietic stem cells to enhance both innate and adaptive immunity. With a focus on solid tumors and hematologic malignancies, Neumedicines aims to address significant unmet needs in oncology, particularly for patients who do not respond to existing immunotherapies.

Upcoming Catalysts (preview)

• TBDPhase 1 clinical trial data readout for HemaMax60% success
• TBDInitiation of Phase 2 clinical trial50% success
• TBDStrategic partnership or licensing deal for HemaMax30% success